Literature DB >> 29275013

Reduced release of TNFα and IP-10 after ex vivo blood stimulation with endotoxin is associated with poor outcome after stroke.

Elzbieta Klimiec1, Katarzyna Kowalska2, Paulina Pasinska3, Joanna Pera4, Agnieszka Slowik5, Tomasz Dziedzic6.   

Abstract

BACKGROUND AND AIMS: The immune response to acute cerebral ischemia plays an important role in the pathophysiology of stroke and could be a therapeutic target. Toll-like receptor 4 (TLR4) is a master regulator of innate immunity. The aim of our study was to determine the association between selected cytokine release after TLR4 activation in blood cells and the outcome after ischemic stroke.
METHODS: We included 156 ischemic stroke patients (median age: 69; 40.4% female). Venous blood was collected at day 3 after the onset of stroke and stimulated ex vivo with lipopolysaccharide (LPS). The LPS-induced level of tumor necrosis factor alpha (TNFα) was used as a proxy of the MyD88-dependent pathway, and interferon-gamma-inducible protein 10 (IP-10) was used as a proxy of the MyD88-independent pathway. The functional outcome was assessed at 3 months after stroke onset.
RESULTS: TNFα (median: 2.2 vs. 3.5 pg/103 monocytes, p < .01) and IP-10 release (median: 0.3 vs. 0. 6 pg/103 monocytes, p < .01) was reduced in patients with a poor outcome. In a multivariate logistic regression analysis adjusted for age, stroke severity, and pneumonia, low TNFα release was associated with a poor outcome (OR: 4.23, 95%CI: 1.64-10.90, p = .03). Similarly, low IP-10 release was related to an unfavorable prognosis (adjusted OR: 3.42, 95%CI: 1.49-8.21, p < .01).
CONCLUSIONS: The reduced release of TNFα and IP-10 after ex vivo blood stimulation with endotoxin is independently associated with poor outcome after stroke. Our results suggest that the inhibition of both the MyD88-dependent pathway and MyD88-independent pathway of TLR4 signaling in blood cells correlates with an unfavorable prognosis in stroke patients.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cytokines; Inflammation; Outcome; Stroke

Mesh:

Substances:

Year:  2017        PMID: 29275013     DOI: 10.1016/j.cyto.2017.12.015

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  5 in total

1.  Glucocorticoid receptor sensitivity in early pregnancy in an African American cohort.

Authors:  Lasha S Clarke; Elizabeth J Corwin; Anne L Dunlop; Allison Hankus; Joshua M Bradner; Sudeshna Paul; Yunshen Jiao; Alicia K Smith; Nikolay Patrushev; Jennifer G Mulle; Timothy D Read; Carol J R Hogue; Bradley D Pearce
Journal:  Am J Reprod Immunol       Date:  2020-05-23       Impact factor: 3.886

2.  Berberine attenuates ischemia-reperfusion injury through inhibiting HMGB1 release and NF-κB nuclear translocation.

Authors:  Jun-Rong Zhu; Hai-Dan Lu; Chao Guo; Wei-Rong Fang; Hong-Dong Zhao; Jun-Shan Zhou; Feng Wang; Yan-Li Zhao; Yun-Man Li; Ying-Dong Zhang; Chang-Qing Yang; Jian-Guo Sun
Journal:  Acta Pharmacol Sin       Date:  2018-11       Impact factor: 6.150

3.  Reduced ex vivo release of pro-inflammatory cytokines and elevated plasma interleukin-6 are inflammatory signatures of post-stroke delirium.

Authors:  Katarzyna Kowalska; Elzbieta Klimiec; Kazimierz Weglarczyk; Joanna Pera; Agnieszka Slowik; Maciej Siedlar; Tomasz Dziedzic
Journal:  J Neuroinflammation       Date:  2018-04-18       Impact factor: 8.322

4.  Glucocorticoid Resistance is Associated with Poor Functional Outcome After Stroke.

Authors:  Anna Maria Lopatkiewicz; Elzbieta Gradek-Kwinta; Mateusz Czyzycki; Joanna Pera; Agnieszka Slowik; Tomasz Dziedzic
Journal:  Cell Mol Neurobiol       Date:  2020-02-27       Impact factor: 5.046

5.  The specific ex vivo released cytokine profile is associated with ischemic stroke outcome and improves its prediction.

Authors:  Elzbieta Klimiec-Moskal; Marcin Piechota; Joanna Pera; Kazimierz Weglarczyk; Agnieszka Slowik; Maciej Siedlar; Tomasz Dziedzic
Journal:  J Neuroinflammation       Date:  2020-01-06       Impact factor: 8.322

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.